Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
Teodora Pene Dumitrescu, Samit R Joshi, Jianfeng Xu, Thomas J Greene, Mark Johnson, Laurie Butcher, Eric Zimmerman, Lindsey Webster, Theresa T Pham, Max Lataillade, Sherene Min, Teodora Pene Dumitrescu, Samit R Joshi, Jianfeng Xu, Thomas J Greene, Mark Johnson, Laurie Butcher, Eric Zimmerman, Lindsey Webster, Theresa T Pham, Max Lataillade, Sherene Min
Abstract
Aims: GSK3640254, a novel, next-generation maturation inhibitor effective against a range of HIV polymorphisms with no cross-resistance to current antiretroviral therapy, could potentially be coadministered with dolutegravir as a 2-drug regimen. In this phase I study, pharmacokinetics and tolerability of GSK3640254 plus dolutegravir were assessed.
Methods: Healthy participants received dolutegravir 50 mg once daily (QD) on Days 1-5 in period 1, GSK3640254 200 mg QD on Days 1-7 in period 2, and dolutegravir 50 mg plus GSK3640254 200 mg QD on Days 1-7 in period 3. All treatments were administered with a moderate-fat meal 30 minutes prior to dosing. Pharmacokinetics parameters were derived by noncompartmental methods, and geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were derived using linear mixed effects models. Adverse events, laboratory measurements, electrocardiography and vital signs were monitored.
Results: Sixteen participants completed the study. GMRs (90% CIs) for dolutegravir area under the plasma concentration-time curve from time 0 to the end of the dosing interval at steady state, maximum observed concentration and plasma concentration at the end of the dosing interval were 1.17 (1.118-1.233), 1.09 (1.044-1.138) and 1.24 (1.160-1.315), respectively. The GMRs (90% CIs) for GSK3640254 were 1.04 (0.992-1.094), 0.99 (0.923-1.065) and 0.10 (0.939-1.056), respectively. Dolutegravir plus GSK3640254 coadministration did not meaningfully alter steady-state exposure to dolutegravir or GSK3640254. No clinically significant trends in tolerability or safety were observed.
Conclusion: Coadministration of GSK3640254 with dolutegravir did not result in clinically significant drug interaction and was well tolerated.
Trial registration: ClinicalTrials.gov NCT03816696.
Keywords: HIV/AIDS; clinical pharmacology; drug interactions; drug safety.
Conflict of interest statement
T.P.D., J.X., T.J.G. and L.B. are employees of and own stock in GlaxoSmithKline. S.R.J., M.J., M.L. and S.M. are employees of ViiV Healthcare. M.J., M.L. and S.M. own stock in GlaxoSmithKline. E.Z, L.W. and T.T.P. are employees of PPD.
© 2021 ViiV Healthcare. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Figures
References
- Arts EJ, Hazuda DJ. HIV‐1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2:a007161.
- Morales‐Ramirez J, Bogner JR, Molina JM, et al. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS‐955176) plus tenofovir/emtricitabine once daily in treatment‐naive HIV‐1‐infected adults: week 24 primary analysis from a randomized Phase IIb trial. PLoS One. 2018;13(10):e0205368.
- Adamson CS, Salzwedel K, Freed EO. Virus maturation as a new HIV‐1 therapeutic target. Expert Opin Ther Targets. 2009;13(8):895‐908.
- Wang D, Lu W, Li F. Pharmacological intervention of HIV‐1 maturation. Acta Pharm Sin B. 2015;5(6):493‐499.
- Wainberg MA, Albert J. Can the further clinical development of bevirimat be justified? Aids. 2010;24(5):773‐774.
- DeJesus E, Johnson M, Dumont E, et al. A phase IIa study of novel maturation inhibitor GSK2838232 in HIV patients. Presented at: Conference on Retroviruses and Opportunitist Infections; March 4‐7, 2019; Seattle, WA
- Joshi SR, Fernando D, Igwe S, et al. Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor. Pharmacol Res Perspect. 2020;8:e00671.
- Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV‐1 management related to the high genetic barrier to drug resistance. Virus Res. 2017;239:1‐9.
- TIVICAY [package insert]. Research Triangle Park, NC: ViiV Healthcare, Inc; 2013.
- Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS guide to pharmacology in 2018: updates and expansion to encompass the new guide to immunopharmacology. Nucleic Acids Res. 2018;46(D1):D1091‐D1106.
- Alexander SP, Fabbro D, Kelly E, et al. The concise guide to pharmacology 2017/18: enzymes. Br J Pharmacol. 2017;174(suppl 1):S272‐S359.
- US Food and Drug Administration . Guidance for industry: clinical drug interaction studies‐Cytochrome P450 enzyme‐ and transporter‐mediated drug interactions. . Accessed May 8, 2020.
Source: PubMed